{"id":90992,"date":"2026-05-19T09:43:21","date_gmt":"2026-05-19T04:13:21","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=90992"},"modified":"2026-05-19T09:43:23","modified_gmt":"2026-05-19T04:13:23","slug":"bio-medica-laboratories-ipo-review-price-band-gmp-may-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bio-medica-laboratories-ipo-review-price-band-gmp-may-2026\/","title":{"rendered":"Bio Medica Laboratories IPO Review: Indore Parenteral Injectable Manufacturer Opens 21 May 2026 at Rs 131-139 on NSE SME"},"content":{"rendered":"

The Bio Medica Laboratories IPO<\/strong> opens for subscription on 21 May 2026 on the NSE SME platform with a price band of Rs 131 to Rs 139 per share. The issue is a combination of a fresh issue of 33,94,800 equity shares and an offer for sale (OFS) of 3,76,800 equity shares, for a total issue of 37,71,600 equity shares, raising approximately Rs 52.4 crore at the upper band. Bio Medica Laboratories Limited is an Indore, Madhya Pradesh-based pharmaceutical company established in 2015, engaged in the manufacturing of parenteral formulations including liquid injectables and dry powder injections for human and veterinary healthcare on a B2B contract manufacturing model.<\/p>

The Bio Medica Laboratories IPO GMP stands at Rs 0 as of 19 May 2026, indicating no grey market premium and an expected listing at or near the Rs 139 issue price. The nil GMP, combined with the relatively small issue size, reflects cautious grey market sentiment ahead of the subscription period opening on 21 May.<\/p>

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n